The FDA on December 20, 2024, granted accelerated approval to BRAFTOVI® with Cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. BRAFTOVI® is a product of Array BioPharma Inc., a subsidiary of Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
